
Bristol Myers’ prized schizophrenia drug stumbles in testing
A brain drug at the center of a recent $14 billion acquisition has failed a large clinical trial, leading some Wall Street analysts to substantially lower their sales forecasts. Bristol Myers Squibb closed a deal to acquire the drug, Cobenfy, and its …